Cytokinetics (CYTK) return on equity (ROE)

Return on equity · fiscal 2021
-88.3%

Cytokinetics (CYTK) earned a return on equity of -88.3% in fiscal 2021 (the year ended December 31, 2021). That is 24.0 percentage points higher than the -112.3% of fiscal 2020. Figures as of 18 Nov 2026, 02:37 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2021
-88.3%
Change on fiscal 2020
+24.0 pts
Highest on record
24.2%fiscal 2009
Lowest on record
-409.8%fiscal 2018
Fiscal years on record
172004–2021

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Cytokinetics return on equity (ROE), in more detail

Across the 17 fiscal years on record (2004–2021), the highest was 24.2% in fiscal 2009 and the lowest -409.8% in fiscal 2018. The fiscal 2021 figure is higher than in 31% of the 16 earlier fiscal years on record, whose median is -57.5%.

History · 17 fiscal years

Return on equity by fiscal year

Cytokinetics return on equity (ROE), year by year

Cytokinetics (CYTK) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2021-88.3% 24.0 pts up
2020-112.3%—
2018-409.8% 293.5 pts down
2017-116.3% 133.8 pts down
201617.4% 72.1 pts up
2015-54.7% 38.8 pts down
2014-15.9% 46.0 pts up
2013-61.9% 4.3 pts down
2012-57.6% 41.7 pts up
2011-99.3% 29.4 pts down
2010-69.9% 94.1 pts down
200924.2% 137.5 pts up
2008-113.3% 64.3 pts down
2007-48.9% 4.8 pts up
2006-53.7% 3.7 pts up
2005-57.4% 22.9 pts down
2004-34.6%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Cytokinetics and comparable companies
CompanyReturn on equityFiscal year
Alkermes ALKS13.3%2025
Cytokinetics CYTK-88.3%2021
ABIVAX ABVX-73.8%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CYTK

Cytokinetics, figure by figure

Cytokinetics (CYTK) overview: price, valuation and scorecardAll health care companies by market value

Cytokinetics return on equity (ROE): questions and answers

What is Cytokinetics's return on equity?

Cytokinetics (CYTK) earned a return on equity of -88.3% in fiscal 2021 (the year ended December 31, 2021). That is 24.0 percentage points higher than the -112.3% of fiscal 2020.

Is Cytokinetics's return on equity high or low compared with its own history?

The fiscal 2021 figure is higher than in 31% of the 16 earlier fiscal years on record, whose median is -57.5%.

What are the highest and lowest return on equity figures on record for Cytokinetics?

Across the 17 fiscal years on record (2004–2021), the highest was 24.2% in fiscal 2009 and the lowest -409.8% in fiscal 2018.

How is Cytokinetics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Cytokinetics (CYTK) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/CYTK/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.